Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06588296 · ClinicalTrials.gov registry record · Phase 3
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight
A Phase 3 study of Obesity and Psoriatic Arthritis, sponsored by Eli Lilly and Company.
- Active
- Registry status
- Phase 3
- Development phase
- 279
- Enrollment target
- 20
- Study locations
NCT06588296: Active Phase 3 study of Obesity and Psoriatic Arthritis, sponsored by Eli Lilly and Company.
NCT06588296 is a Phase 3 study of Obesity and Psoriatic Arthritis that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 279 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (66% lower). The trial reports 20 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06588296, a Phase 3 study of Obesity and Psoriatic Arthritis, is active but no longer recruiting, sponsored by Eli Lilly and Company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 279 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to demonstrate that when participants with psoriatic arthritis and obesity or overweight in the presence of at least 1 weight-related comorbid condition receive ixekizumab and tirzepatide concomitantly administered, participants see improvement in their psoriatic arthritis and achieve weight reduction compared to when receiving ixekizumab. Participation in this study includes up to 12 visits and could last up to 61 weeks including screening, open label treatment period, and post-treatment follow-up period.
Primary Outcome
ACR50 is defined as at least 50% improvement in the ACR core set values. The percentage improvement in the ACR scores is determined by an improvement of at least 50% in the number of Tender Joint Count (TJC) (0-68) and Swollen Joint Count (SJC) (0-66) and an improvement of at least 50% in at least 3 of these 5 assessments: 1. Patient's Assessment of Arthritis Pain Visual Analog Scale (VAS) 2. Patient's Global Assessment of Disease Activity Numeric Rating Scale (PaGADA \_NRS) 3. Physician's Glob
Conditions Studied
Interventions
- DRUG Tirzepatide
- DRUG Ixekizumab
Study Locations (20)
Arizona
- AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Avondale - Avondale
- AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Chandler - Chandler
- AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Flagstaff - Flagstaff
- AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Gilbert - Gilbert
- AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Glendale - Glendale
- AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Mesa - Mesa
- AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Phoenix PV - Phoenix
- AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Sun City - Sun City
- AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Tucson - Tucson
- AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Tucson Southeast - Tucson
California
- Medvin Clinical Research - Apple Valley - Apple Valley
- Medvin Clinical Research - Covina - Covina
- Newport Huntington Medical Group - Huntington Beach
- Purushotham & Akther Kotha MD, Inc - La Mesa
- Medvin Clinical Research - Riverside - Riverside
- Rheumatology Center of San Diego - San Diego
- Medvin Clinical Research - Temecula - Temecula
- Cohen Medical Centers - Thousand Oaks
- Medvin Clinical Research - Tujunga - Tujunga
- Medvin Clinical Research - Whittier - Whittier
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 279 participants |
| Start Date | 2024-09-24 |
| Est. Completion | 2026-04 |
| Phase | Phase 3 |
What the registry record for NCT06588296 still lists
NCT06588296 is an interventional study that assigns participants to a tested intervention. The registered 279 participants enrollment target is mid-sized for trials with a published cap, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (66% lower).
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Tirzepatide is the first listed.
NCT06588296 names 20 study sites across 2 states, led by Arizona, California.
Frequently Asked Questions
What is clinical trial NCT06588296 about?
NCT06588296 is a clinical study titled "Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight". The main purpose of this study is to demonstrate that when participants with psoriatic arthritis and obesity or overweight in the presence of at least 1 weight-related comorbid condition receive ixekizumab and tirzepatide concomitantly administered, participants see improvement in their psoriatic ar...
What is the current status of trial NCT06588296?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 279 participants. The study started on 2024-09-24. Estimated completion is 2026-04.
What conditions does trial NCT06588296 study?
This clinical trial studies the following conditions: Obesity, Psoriatic Arthritis.
What interventions are being tested in trial NCT06588296?
The interventions under investigation include: Tirzepatide (DRUG), Ixekizumab (DRUG).
Who is sponsoring clinical trial NCT06588296?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06588296 being conducted?
This trial has 20 study locations across Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06588296's enrollment target sits among peer trials
279 240th of 1053 higher than 814 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
RECRUITING · Phase 3
-
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
RECRUITING · Phase 3
-
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
RECRUITING · Phase 3
-
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04783857 · 279 participants · Phase 4
Modifying Progesterone and Estradiol Levels to Prevent Postpartum Cigarette Smoking Relapse and Reduce Secondhand Smoke Exposure in Infants and Children
- NCT05407324 · 279 participants · Phase 2
Dazucorilant in Patients With Amyotrophic Lateral Sclerosis
- NCT06299748 · 279 participants
A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.
- NCT06582784 · 279 participants · NA
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI